SecBot SecBot
8-K ·Filed Nov 13, 2026

MIST

Milestone Pharmaceuticals Inc.
NEUTRAL
Impact 5/10
Horizonmonths Processed8d 23h ago SEC0001104659-26-126519
8-K Item 2.02: Earnings release
Actionable Insight • Neutral

Monitor prescription growth trajectory and payer coverage expansion for CARDAMYST, as well as enrollment updates for the Phase 3 AFib-RVR trial, which is the primary catalyst for 2H 2028.

DirectionNeutral
Confidencehigh
Horizonmonths

CARDAMYST

● Neutral Named in this 8-K
Impact
Phase
Approved
Time to market
Already approved and commercially launched in the US (FDA approval December 2025, launch began February 2026). Also approved in China (September 2026).
Next catalyst
None dated

What to watchCARDAMYST is already approved and launched, so the next major catalyst is the Phase 3 ReVeRA-301 topline readout for AFib-RVR, which could expand the addressable market significantly. The company's Q3 2026 earnings today showed accelerating prescription growth (73% sequential revenue increase) but also a 30% cost-cutting plan, and the stock fell ~20% on the day. Watch for quarterly prescription and revenue trends as the key near-term value drivers.

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5
Entry
$0.5200
T+0 close · Nov 13, 2026 · via day close
Latest settled
−28.63%
T+5 · $0.3711
Vs SPY
−20.08%
α at T+5
Next horizon
T+20
in 22d
  1. T+0 · Nov 13 $0.5200entry
  2. T+1 · 6d ago −29.81%α −27.90% · $0.3650
  3. T+5 · 2d ago −28.63%α −20.08% · $0.3711
  4. T+20 · in 22d Pending
  5. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Milestone Pharmaceuticals reported Q3 2026 product revenue of $1.0M, up 73% QoQ, and announced a 30% operating expense reduction to extend cash runway into late 2028, beyond the expected Phase 3 AFib-RVR data readout in 2H 2028. The CFO and CMO have departed, and the company amended its convertible notes to extend the PIK interest period to March 2029.

Key Financial Metrics

EPS
−$0.18
est −$0.21 · +14.3%
Revenue
$1.0M
est $1.0M · 0.0%
Rating
beat

Key Facts

  • Q3 2026 product revenue $1.0M, up 73% from Q2 2026 ($0.6M)
  • Operating expenses to be reduced by approximately 30%
  • Cash and equivalents $145.4M as of Sep 30, 2026; runway extended into late 2028
  • CFO Amit Hasija and CMO David Bharucha have departed; Anthony Krick named Principal Financial Officer
  • Amendment to RTW note purchase agreement extends PIK interest period to March 2029
  • Phase 3 ReVeRA-301 trial in AFib-RVR on schedule; topline data expected 2H 2028
  • Payer coverage increased to approximately two-thirds of commercially covered lives
  • One-time charges of approximately $2M expected for workforce reduction

Financial Impact

Q3 2026 product revenue $1.0M; net loss $25.8M ($0.18/share); cash $145.4M; operating expense reduction of ~30%

revenuecash runwayoperating expenses

Risk Factors

  • Early-stage commercial launch with modest revenue ($1.0M quarterly); profitability far off
  • Shareholders' deficit of $6.2M as of Sep 30, 2026, indicating negative equity
  • Dependence on single product CARDAMYST and pipeline candidate etripamil for AFib-RVR
  • Leadership departures (CFO, CMO) create execution risk during restructuring

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
85% bullish (13 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001104659-26-126519
Document: tm2629645d1_8k.htm0001104659-26-126519
Document: 0001104659-26-126519-index-headers.html0001104659-26-126519
Document: 0001104659-26-126519-index.html0001104659-26-126519
Document: 0001104659-26-126519.txt0001104659-26-126519
8-K Data (Synthetic)0001104659-26-126519

Track record

13 reports on MIST

Performance horizon

5 of 7 bullish or bearish reports moved the stock their way by T+5. Best: +50.00% at T+20 after the Mar 20, 2026 report. 6 of 7 went positive at some point.

Filters
  1. Nov 20, 20261d ago SC 13G/A Neutral 4/10 Entry $0.3752 Now $0.3710 −1.12% settles Nov 30
  2. Nov 19, 20262d ago 3 Neutral 2/10 Entry $0.4130 Now $0.3710 −10.17% settles Nov 30
  3. Nov 13, 20268d ago 8-K Neutral 5/10 Viewing Entry $0.5200 to $0.3711 Now $0.3710 −28.65% ▼ −28.63% −20.08% vs SPY
  4. Oct 28, 202624d ago 8-K Bearish 7/10 Entry $0.7896 to $0.6925 Now $0.3710 +53.01% ▲ +12.30% +7.57% vs SPY
  5. Sep 3, 202611w ago 8-K Bullish 6/10 Entry $1.20 to $0.9494 Now $0.3710 −69.08% ▼ −20.88% −19.67% vs SPY
  6. Aug 21, 202613w ago Press Release Bullish 7/10 Entry $1.06 to $1.16 Now $0.3710 −64.83% ▲ +9.95% +9.48% vs SPY
  7. Aug 12, 202614w ago 8-K Bearish 6/10 Entry $1.13 to $1.08 Now $0.3710 +67.02% ▲ +4.00% +3.56% vs SPY
  8. May 26, 202625w ago EFFECT Bearish 6/10 Entry $1.40 to $1.32 Now $0.3710 +73.50% ▲ +5.71% +6.93% vs SPY
  9. May 13, 202627w ago S-3 Bearish 6/10 Entry $1.63 to $1.52 Now $0.3710 +77.24% ▲ +6.75% +6.03% vs SPY
  10. May 13, 202627w ago 8-K Neutral 5/10 No price data
Showing 10 of 13

US Market Status

Market Closed · Opens Mon (26h 4m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 13, 2026